Definitive chemoradiotherapy and salvage chemotherapy for patients with isolated locoregional recurrence after radical resection of primary pancreatic cancer

• Main Authors: Shi W, Jiang R, Liang F, Yu G, Long J, Zhao J
• Format: Article
• Language: English
• Published: Dove Medical Press 2019-05-01
• Series: Cancer Management and Research
• Subjects: Pancreatic cancer; isolated locoregional recurrence; locoregional oligo-recurrence; chemoradiotherapy; radiotherapy.
• Online Access: https://www.dovepress.com/definitive-chemoradiotherapy-and-salvage-chemotherapy-for-patients-wit-peer-reviewed-article-CMAR

Wei Shi,1,2 Rui Jiang,1,2 Fei Liang,3 Genhua Yu,4 Jiang Long,2,5 Jiandong Zhao1,21Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of China; 2Department of Oncology, Shanghai Medical College, Shanghai, People’s Republic of China; 3Clinical Statistic Center, Shanghai Cancer Center and Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China; 4Department of Radiation Oncology, Zhebei Mingzhou Hospital, Huzhou City, Zhejiang Province, People’s Republic of China; 5Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People’s Republic of ChinaPurpose: The objective of this study was to analyze the safety and efficacy of definitive chemoradiotherapy and salvage chemotherapy in pancreatic cancer (PC) patients with isolated locoregional recurrence after radical resection and assess the factors associated with tumor response.Patients and methods: A retrospective study of isolated locoregional recurrent PC patients who were treated with definitive chemoradiotherapy and salvage chemotherapy at our institution between 2012 and 2017 was conducted. Medium dose of 56.0 Gy (range: 54.0 Gy - 60.2 Gy) in 1.8 Gy to 2.15 Gy daily fractions was prescribed to the PTV-G and 50.4 Gy was prescribed to the PTV-C. Patients received chemotherapy before, at the same time with or after radiotherapy. The overall survival (OS) and freedom from locoregional progression (FFLP) rates were estimated by the Kaplan–Meier method, and the log-rank test was performed to compare survival curves. The Cox regression was used to identify factors affecting response to treatment and survival.Results: Thirty-one patients were included. The median interval from the resection of primary PC to the diagnosis of the locoregional recurrence (DFI) was 7.4 months (range 0.2–44.6). Within a median follow-up from the start of radiotherapy (RT) of 31.7 months (95% CI: 20.0–43.5 months), the medium OS and FFLP rates from the start of RT were 23.6 and 12.0 months, respectively. DFI >6 months was shown to be a significant factor associated with favorable OS. Acute and late toxicity of grade 3 occurred in 3 patients (9.7%) and 1 patient (3.2%) respectively. No grade 4 toxicity or higher occurred.Conclusions: This single-institution retrospective analysis identified definitive chemoradiotherapy and salvage chemotherapy to be a feasible and tolerable treatment strategy for patients with isolated locoregional recurrence after radical resection of primary PC.Keywords: pancreatic cancer, isolated locoregional recurrence, locoregional oligo-recurrence, chemoradiotherapy, radiotherapy